Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/16791
Título
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022
Autor(es)
Rose, Angela Mc | Nicolay, Nathalie | Sandonis-Martin, Virginia ISCIII | Mazagatos, Clara ISCIII | Petrović, Goranka | Baruch, Joaquin | Denayer, Sarah | Seyler, Lucie | Domegan, Lisa | Launay, Odile | Machado, Ausenda | Burgui, Cristina | Vaikutyte, Roberta | Niessen, F Annabel | Loghin, Isabela I | Husa, Petr | Aouali, Nassera | Panagiotakopoulos, George | Tolksdorf, Kristin | Horváth, Judit Krisztina | Howard, Jennifer | Pozo Sanchez, Francisco ISCIII | Gallardo, Virtudes | Nonković, Diana | Džiugytė, Aušra | Bossuyt, Nathalie | Demuyser, Thomas | Duffy, Róisín | Luong Nguyen, Liem Binh | Kislaya, Irina | Martínez-Baz, Iván | Gefenaite, Giedre | Knol, Mirjam J | Popescu, Corneliu | Součková, Lenka | Simon, Marc | Michelaki, Stella | Reiche, Janine | Ferenczi, Annamária | Delgado-Sanz, Concepcion ISCIII | Lovrić Makarić, Zvjezdana | Cauchi, John Paul | Barbezange, Cyril | Van Nedervelde, Els | O'Donnell, Joan | Durier, Christine | Guiomar, Raquel | Castilla, Jesús | Jonikaite, Indrė | Bruijning-Verhagen, Patricia Cjl | Lazar, Mihaela | Demlová, Regina | Wirtz, Gil | Amerali, Marina | Dürrwald, Ralf | Kunstár, Mihály Pál | Kissling, Esther | Bacci, Sabrina | Valenciano, Marta | I-MOVE-COVID-19 hospital study team | VEBIS hospital study team
Fecha de publicación
2023-11
Cita
Euro Surveill. 2023 Nov;28(47):2300187.
Idioma
Inglés
Tipo de documento
research article
Resumen
Introduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received < 150 and ≥ 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition. Results: We included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received ≥ 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively. Conclusions: Our results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose.
Palabras clave
MESH
COVID-19 | Pneumonia | Humans | Adult | COVID-19 Vaccines | Vaccine Efficacy | SARS-CoV-2 | Hospitalization | Europe | RNA, Messenger
Versión en línea
DOI
Aparece en las colecciones
Ficheros en el ítem
- Nombre:
- VaccineEffectivenessAgainstCOV ...
- Tamaño:
- 764.0Kb
- Formato:
- Descripción:
- Articulo
- Nombre:
- Supplement_VaccineEffectivenes ...
- Tamaño:
- 285.7Kb
- Formato:
- Descripción:
- supplementary material